Results For The Quarter Ended June 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare Limited filed its Q1 FY26 results on August 4, 2025. On a standalone basis, revenue from operations fell sharply to ₹1,837.37 lakhs, down roughly 76% from ₹7,769.62 lakhs in the same quarter last year. The standalone company swung to a loss of ₹36.51 lakhs, compared with a profit of ₹163.60 lakhs in Q1 FY25, with EPS turning marginally negative. Total expenses of ₹2,221.55 lakhs exceeded total income, driven largely by purchases of stock-in-trade and inventory changes. On a consolidated basis (first time being reported, so no prior-year comparable), revenue was ₹11,336.67 lakhs with a profit after tax of ₹464.88 lakhs and EPS of ₹0.05. The statutory auditor, Taori Sandeep & Associates, issued an unmodified review report with no qualifications on both standalone and consolidated results.
The steep standalone revenue drop and the swing into a loss are red flags for shareholders, suggesting the parent-level business shrank significantly year-on-year. However, the consolidated picture shows the Singapore subsidiary (Remlife Global PTE) is now the main contributor to revenue and profit, so investors should watch how the parent and subsidiary split evolves over coming quarters.